Applied Data Research Release: Emerging Targets and Therapeutic Approaches Driving Activity in Autoimmune Disease Therapeutics  
2/18/2008 7:28:48 AM

(Nashua, NH) – Autoimmune diseases can be considered one of the silent tragedies of human suffering. Leading a group of ailments that includes migraine, dementia, and depression, autoimmune conditions cause daily anguish for a significant portion of the population and yet remain underserved by the medical establishment and the healthcare community. The refractory nature of this family of diseases is routed in the complexities and genetic underpinnings of the human immune response, resulting in a set of disease targets that are at once physiologically ubiquitous and highly individualized.

Until recently, autoimmune disease patients were given little hope for effective treatment. But the convergence of improved elucidation of autoimmune disease mechanisms and the ability to design and manufacture recombinant proteins capable of attenuating the immune system cascade has led to systemic treatments that have demonstrated the ability to provide some degree of relief from autoimmune symptoms in a significant number of patients.

This sector is positioned for rapid growth. Biological drugs for multiple sclerosis, a group led by Biogen Idec’s Avonex, had a worldwide value of $5.6 billion in 2006, an increase of just under14% from the previous year. Biologicals indicated for rheumatoid arthritis, psoriasis and associated diseases reached $7.9 billion worldwide in 2006, a year-to-year increase of 19%. A number of potentially important pipeline drugs hold the promise of future improvements in patient outcomes. These developments are examined in a new and comprehensive report – Autoimmune Disease Therapeutics: Targets, Technologies and

Therapies. The report analyzes current autoimmune therapeutics and assesses the next generation of candidates and their probable impact on treatment options and the competitive landscape.

More information is available at .

About Applied Data

Applied Data Research is a healthcare therapeutics consulting firm focused on medical market strategies, product commercialization, venture development, and market research. We assist medical market participants in achieving their business objectives through the creation of detailed business development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Contact: Greg Stone Voice: 603-595-6225 Fax: 603-804-0466

Source: Applied Data Research